ATM F858L

CI-VAR-00001143Explore in graph →CIViC 1881

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Lung Neoplasm1
ATM F858L	Selumetinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID5127 In a PDX lung cancer model containing a heterozygous ATM F858L mutation, the MEK inhibitor selumetinib completely blocked tumor growth and induced tumor regression. PMID 27922010 · Smida et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.